ARTIVION INC (AORT)
Health Care · medical devices · NYSE
Artivion is a leader in surgical solutions for aortic disease, combining proprietary stent grafts, mechanical heart valves, surgical sealants, and implantable tissue services.
What ARTIVION INC does
Artivion manufactures and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures, primarily for treating aortic disease. The company's core product lines include aortic stent grafts (both arch and abdominal), On-X mechanical heart valves, surgical sealants (BioGlue), and preservation services for implantable cardiac and vascular tissues. It operates through two segments: Medical Devices and Preservation Services, with a global footprint supported by subsidiaries including JOTEC in Germany and On-X Life Technologies in Texas.
Themes: Aortic disease treatment, Cardiac and vascular surgery, Stent graft systems, Mechanical heart valves, Surgical adhesives and sealants, Implantable tissues and biologics, Endovascular interventions, Tissue banking and preservation services
Fundamentals
- Price$28.08 as of 2026-08-21 close
- Market cap$1.4B as of 2026-08-21
- 1-year return-34.9% 2025-08-21 close $43.14 → 2026-08-21 close $28.08
- P/E117.64 as of 2026-08-24
- Net margin+2.5% as of 2026-08-24
- Gross margin+64.5% as of 2026-08-24
- ROE+2.7% as of 2026-08-24
- Debt / equity0.49 as of 2026-08-24
- Revenue growth (YoY)+17.6% as of 2026-08-24
- Revenue CAGR (3y)+12.0% SEC XBRL
- Beta1.23 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How AORT compares in its sector
- price-to-earnings ratiotop 10% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which AORT reported a dividend payment is FY2015, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2015 ratio would not describe AORT today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2015) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How ARTIVION INC looks technically
ARTIVION INC (AORT) is trading 20.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 104 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 6 trading days ago. It is 41.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 20.2% below its 200-day average, the long-term trend line — a long-term downtrend | -20.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $24.95 | $24.95 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $35.19 | $35.19 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 25.79. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 104 trading days ago — a "death cross", a bearish long-term signal | 104 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 30.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 56.6 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($25.79 to $30.14) — its "stochastic" reading is 53 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 52.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $48.25 | $48.25 |
|---|---|---|
| From the 52-week high | it is 41.8% below its 52-week high (its highest price of the past year) | -41.8% |
| Above the 52-week low | it is 46.6% above its 52-week low (its lowest price of the past year) | +46.6% |
| Below the 52-week high | it is 41.8% below its highest point of the past year | 41.8% |
| Since a 20-day breakout | it made a new 20-day high about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day high about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $48.25 (set on 2025-12-17) | $48.25 |
| Given back of the 52-week move | over the past year its closes ranged ($20.10 to $47.63), and it has recovered roughly a quarter of its fall from last year’s high — 29% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $37.11 to $37.99. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 29.0% |
| From the all-time high | it is 41.8% below its all-time high | -41.8% |
| Nearest price level | it is trading 0.6% below a resistance level at $28.24 — a price it turned at four times since 2024-12-09, most recently on 2026-08-03. Since 2024-08-21 it has 6 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.6% |
| All-time low | its lowest closing price on record is $1.40 (set on 2002-08-15) | $1.40 |
| Above the all-time low | it is 1905.7% above its all-time low | +1,906% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 81% of it) | 19th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.22 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.22 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $25.75 and $29.49 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $25.75 – $27.62 – $29.49 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is trading 5.8 daily ranges below its 200-day average price (20.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.73× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.1% since the prior reading | +0.1% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 2.7% above the previous close 36 sessions ago and has not traded back through the level it left behind at 22.47 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.7% |
| Gap filled | a 6.0% gap up opened on 2026-06-16 has been "filled" 42 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 42 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 10.3 percentage points (the stock gained 12.6% while the market gained 2.3%) | +10.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 20.2 percentage points (the stock gained 23.3% while the market gained 3.1%) | +20.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 37.8 percentage points (the stock lost 26.7% while the market gained 11.1%) | -37.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 55.4 percentage points (the stock lost 34.9% while the market gained 20.5%) | -55.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a strong uptrend, with buyers in control — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 17.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $29.40 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | -4.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is roughly break-even. That average is $27.98 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +0.3% |
Price levels it has turned at before
AORT last closed at $28.08 on 2026-08-21. Since 2024-08-21 it has turned at 6 prices below its last close and 12 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $28.24 | Resistance | 0.6% above the last close | turned there four times · 2024-12-09 to 2026-08-03 |
| $27.51 | Support | 2.0% below the last close | turned there five times · 2024-08-30 to 2025-01-02 |
| $29.55 | Resistance | 5.2% above the last close | turned there twice · 2024-12-26 to 2025-05-19 |
| $26.04 | Support | 7.3% below the last close | turned there six times · 2024-09-17 to 2026-08-05 |
| $30.17 | Resistance | 7.4% above the last close | turned there six times · 2024-11-07 to 2025-08-01 |
| $24.91 | Support | 11.3% below the last close | turned there four times · 2024-10-10 to 2026-05-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $25.79.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $29.23 and $34.79 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · lagging the market · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$42.03 range $38.00 – $48.00; median $41.60
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AORT
- Consensus EPS estimate$0.08667 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant competition from larger well-capitalized competitors with greater financial resources, manufacturing efficiency, tissue processing capacity, and marketing capabilities that could render Artivion's products non-competitive or obsolete","Foreign exchange exposure from sales denominated in multiple currencies (Euros, Brazilian Reals, Polish Zlotys, British Pounds, Canadian Dollars, Swiss Francs) that materially impact revenue when translated to US Dollars","Regulatory approval and clearance risks for new products and expanded indications; competitors may obtain FDA or foreign regulatory approvals sooner, potentially delaying commercialization of Artivion's pipeline"]
What changed in the latest 10-Q
AI-assisted comparison of AORT's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) reports quarterly revenues of $116.3 million for three months ended March 31, 2026, compared to $98.978 million for three months ended March 31, 2025
- Newer filing adds revenue table comparing March 31, 2026 vs March 31, 2025 periods only
- Newer filing adds constant currency revenue reconciliation table for March 31 comparison periods
- Newer filing adds geographic revenue breakdown (North America, EMEA, APAC, Latin America) for March 31 periods
- Newer filing includes detailed Aortic Stent Grafts section with March 31, 2026 performance metrics
- Removed:
- Older filing (2025-11-07) reports quarterly revenues of $113.4 million for three months ended September 30, 2025, compared to $95.779 million for three months ended September 30, 2024 - removed in newer filing
- Older filing includes nine-month revenue data for September 30, 2025 and 2024 - not present in newer filing
- Older filing includes nine-month constant currency reconciliation table - removed in newer filing
- Older filing includes detailed discussion of nine-month results - not present in newer filing
- Older filing's Aortic Stent Grafts section references E-vita Thoracic 3G without 'products' designation; newer filing adds 'products' to product names in some contexts
- Reworded:
- Older filing states 'E-vita Thoracic 3G' while newer filing consistently refers to 'E-vita Thoracic 3G products' in product listings
- Reporting period changed from September 30, 2025 to March 31, 2026 throughout MD&A sections
- Prior year comparison changed from September 30, 2024 to March 31, 2025 throughout sections
- Older filing discusses 'three and nine months ended September 30, 2025' while newer filing discusses only 'three months ended March 31, 2026'
- Constant currency revenue increase metric changed from 16% (nine months) and 18% (three months, older filing September 30, 2025) to 12% (three months, newer filing March 31, 2026)
- Notes:
- The two filings cover different fiscal periods (Q3 2025 ended September 30, 2025 vs Q2 2026 ended March 31, 2026), making direct operational comparisons subject to seasonal and temporal differences
- The newer filing appears to be truncated and does not include the complete MD&A section shown in the older filing
Risk Factors
- Added:
- Added phrase 'and the ongoing Iranian conflict in the Middle East' to geopolitical risks section (2026-05-08 filing)
- Added phrase 'on May 7, 2026, we elected to exercise the option to acquire Endospan pursuant to the Endospan Option Amendment,' describing Endospan acquisition decision (2026-05-08 filing)
- Added phrase 'We have not experienced any material disruption of supply from Endospan related to the war in Iran;' specifying Iran-related supply chain context (2026-05-08 filing)
- Removed:
- Removed specific payment fulfillment statement 'In September 2025 we fulfilled that payment obligation.' (was in 2025-11-07 filing)
- Removed phrase 'and instability in the Middle East' and replaced with more specific conflict language (2025-11-07 filing)
- Reworded:
- Changed 'instability in the Middle East' to 'the ongoing Iranian conflict in the Middle East' and added 'and in particular the ongoing conflict in Iran' for greater specificity (2026-05-08 vs 2025-11-07)
- Changed Italian government assessment description from 'which resulted in a payment obligation of approximately 0.1 million euros' to 'our potential repayment exposure for the entire 2019–2025 period is estimated at approximately $2.3 million,' shifting from past payment obligation to future exposure estimate (2026-05-08 vs 2025-11-07)
- Changed 'Although we do not have any direct operations' to 'Although currently we do not have any direct operations' (2026-05-08 vs 2025-11-07)
- Changed 'the NEXUS family of products are solely manufactured by Endospan' to 'we elected to exercise the option to acquire Endospan... the NEXUS family of products are solely manufactured by Endospan,' adding acquisition context (2026-05-08 vs 2025-11-07)
- Changed 'We have not experienced any material disruption of supply from Endospan' to 'We have not experienced any material disruption of supply from Endospan related to the war in Iran,' adding geographic specificity (2026-05-08 vs 2025-11-07)
- Notes:
- Text provided appears truncated at the end of both filings; comparison limited to complete sections present
- Page number changed from 37 (2025-11-07) to 34 (2026-05-08), possibly reflecting document reorganization
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 4 sells ($2M) — 4 selling insiders
- Last 90 days0 buys · 6 sells ($3M) — 4 selling insiders
- Last 180 days0 buys · 6 sells ($3M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-19. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AORT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for AORT from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding AORT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 10,811,423
- Reported value $395,914,311
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AORT had 2,705,501 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AORT had 5.55% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.76 days to cover at the same settlement.
- Reported short interest (shares) 2,705,501
- Short interest (% of shares outstanding) 5.55%
- Prior settlement (shares) 2,498,637
- Reported change 8.28%
- Days to cover (reported) 4.76
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- W. L. Gore & Associates
- Cook Medical
- Edwards Lifesciences (EW)
- Terumo Aortic
- Getinge AB (GETI-B.ST)
- CryoLife (historical)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AORT vs…
Frequently asked questions
What does ARTIVION INC (AORT) do?
Artivion manufactures and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures, primarily for treating aortic disease. The company's core product lines include aortic stent grafts (both arch and abdominal), On-X mechanical heart valves, surgical sealants (BioGlue), and preservation services for implantable cardiac and vascular tissues.
What sector is ARTIVION INC (AORT) in?
ARTIVION INC (AORT) is classified in the Health Care sector. Its industry is medical devices. It trades on NYSE.
Who are ARTIVION INC's (AORT) competitors?
Notable peers of ARTIVION INC (AORT) include Medtronic, W. L. Gore & Associates, Cook Medical, Edwards Lifesciences and Terumo Aortic. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in AORT?
Yes — we hold 1 matched STOCK Act disclosure for AORT from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ARTIVION INC (AORT) overbought or oversold right now?
ARTIVION INC (AORT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AORT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.